PRR Project
Assistant Professor in Clinical Pharmacology
Project sheet
Name
Assistant Professor in Clinical PharmacologyTotal project amount
84,86 thousand €Amount paid
84,86 thousand €Non-refundable funding
84,86 thousand €Loan funding
0 €Start date
06.10.2025Expected end date
31.03.2026Dimension
ResilienceComponent
Qualifications and SkillsInvestment
Science Plus TrainingOperation code
02/C06-i06/2024.P2023.15190.TENURE.003Summary
Clinical pharmacology is a translational scientific discipline which strives to understand the actions and behaviors of drugs in humans by combining it with the knowledge of human pharmacology. The study of clinical pharmacology is fundamental to our understanding of how drugs are processed by our bodies and how they affect human physiology.Clinical pharmacology contributes to a better understanding of the relationship between a drug’s dose and its effect, the variability in response to a drug or therapy, why some patients experience adverse effects (AEs), how AEs can be minimized, and more. Understanding these aspects of a drug’s action (pharmacodynamics) and disposition (pharmacokinetics), helps drug developers achieve safe, effective, and optimal therapeutic outcomes for patients.As Assistant Professor in Clinical Pharmacology the candidate will work at the Department of Pharmacy, Pharmacology and Health Technologies, within the Scientific Area of Pharmacological Sciences and with a special focus in Translational Research and Clinical Pharmacology bridging the path from early research to interaction with different areas to reduce the gap to first in human administration and further clinical development, supporting original research projects but also collaborating within existing research projects within the hiring institution (Faculdade de Farmácia da Universidade de Lisboa) and the local research institution (iMed.UL). It is expected that as Assistant Professor in Clinical Pharmacology, the candidate will:represent non-clinical and clinical pharmacokinetics and pharmacodynamics in research project teams, both internally in the collaboration within iMed.ULisboa / FFUL and externally, collaborating with other stakeholders.provide in-depth expertise to the overall non-clinical and clinical drug development of new drug candidates (including drug repurposing and external collaboration with the pharmaceutical industry and/or regulatory authorities).provide support to non-clinical and clinical pharmacology development including support to, but not limited to, formulation development/biopharmaceutical aspects, pharmacokinetics, and pharmacodynamics in the entire extent of these domains.Learn and apply emerging modelling and simulation methodologies with a view to enhance drug development program efficiency.have a leading role in implementing and promoting innovative methodologies and approaches.study biomarkers, pharmacokinetics, drug metabolism, and/or pharmacogenomics from a cellular level to a population level.collaborate with the pharmacovigilance unit hosted by FFUL.apply for competitive funding to augment research support and gain a track record of successful applications and develop experimental research activities.provide training and expert advice to junior colleagues and interfaces.participate in the Department’s education activities, including, but not limited to, Didactics, Seminars, and Journal Club activities. Also, participation in the Department’s training and mentoring of graduate students and postdoctoral fellows is expected.The requirements to fulfil the position of Assistant Professor in Clinical Pharmacology are the following:PhD in Pharmacy or Pharmaceutical Sciences, or other life sciences (if in-depth training has been acquired, and may be demonstrated, in drug development, general pharmacology, clinical pharmacokinetics and pharmacodynamics).Advanced level knowledge of Non-Clinical and Clinical Pharmacology aspects in drug development such as Pharmacokinetics & Pharmacodynamics (PK/PD) principles, biopharmaceutics, and clinical pharmacology aspects in patient trials, including the clinical pharmacology of special populations such as pediatrics.Thorough understanding of pre-clinical and clinical drug metabolism, PK/PD, drug-drug/food interactions.Working knowledge in Model Informed Drug Development (MIDD); pharmacokinetic software programs incl. understanding of modeling tools e.g. translational PK/PD modeling, Physiologically Based Pharmacokinetics (PBPK), Pharmacometrics / Populational Pharmacokinetics (popPK), Quantitative Systems Pharmacology (QSP), Quantitative Systems Toxicology (QST) and Model-Based Meta-Analysis (MBMA).Thorough knowledge on Clinical Pharmacology related guidelines from the main regulatory agencies to better bridge academic drug development and the knowledge transfer to other stakeholders.Knowledge in biomarkers, pharmacogenomics, and biostatistics.Excellent oral and written communication, negotiation, and presentation skills.Distinct social and leadership skills.Great sense of responsibility and interest in interdisciplinary work.This position is ideal for a highly motivated researcher with a track record of research excellence. To be successful in this position, candidates should have a history of independent extramural funding and published record of scholarly achievement and scientific productivity.
Beneficiaries
The two types are::
- Direct Beneficiaries are those whose funding and projects to implement are part of the Recovery and Resilience Plan that has been negotiated and approved by the European Union;
- Final Beneficiaries are those whose funding and projects to implement are approved following a selection process through Calls for Applications.
Call for applications
As part of the Call for Applications, submissions are requested to select the projects and final beneficiaries to whom funding will be awarded. Specific selection criteria are defined for each call, which must be reflected in the applications submitted and assessed.
The project is appraised on the basis of its compliance with the selection criteria laid down in the calls for applications, and a final score may be awarded, where applicable.
Final evaluation score
The components for calculating the assessment score can be found in the selection criteria document mentioned below.
Selection criteria
Beneficiaries
Intermediate beneficiaries
Procurement
Beneficiaries representing public entities implement their project by signing one or more contracts with suppliers for goods or services through public procurement procedures.
To ensure and provide the utmost transparency in all these contracts, a list of the contracts that were signed under this project is available here, along with the information available on the Base.Gov platform. Please note that, according to the legislation in force at the time the contract was signed, some exceptions do not require the publication of the contracts signed on this platform, and, therefore, no information is available in such cases.
Geographic distribution
84,86 thousand €
Total amount of the project
Percentage of the amount already paid for implementing projects
, 100 %,Where was the money spent
By county
1 county financed .
-
Lisboa 84,86 thousand € ,